Electroencephalography

Newron Announces Half-Year 2021 Results

Retrieved on: 
Thursday, September 16, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Anders (singer), Central nervous system, Patient, Medication, PD, XETRA, EEG, Abbreviated New Drug Application, Paragraph, Orange Book, Risk, Safety, Peripheral nervous system, Toxicity, Tablet, EUR, Peripheral neuropathy, CNS, EIB, Schizophrenia, Sale, Electroencephalography, Pharmaceutical industry

Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its operational highlights and financial results for the half-year ended June 30, 2021.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its operational highlights and financial results for the half-year ended June 30, 2021.
  • In April, Newron announced encouraging results from two short-term explanatory studies in evenamide: study 010 in 56 healthy volunteers, and study 008 in 138 outpatients with chronic schizophrenia, receiving treatment with a second-generation atypical antipsychotic.
  • Based on this encouraging data and supported by the pre-clinical results published last year confirming the absence of toxicity, Newron, on September 6, 2021, initiated study 008A, the first potentially pivotal study with evenamide in patients with chronic schizophrenia.
  • Newron believes that positive results from this study would qualify the trial as the first adequate and well-controlled (pivotal) study with evenamide in patients with schizophrenia who are inadequate responders to antipsychotics.

DGAP-News: Newron announces Half-Year 2021 results

Retrieved on: 
Thursday, September 16, 2021
Anders (singer), Central nervous system, FDA, Patient, PD, XETRA, EEG, Abbreviated New Drug Application, Paragraph, Orange Book, Company, CEST, Risk, Safety, Peripheral nervous system, Toxicity, Tablet, EUR, Peripheral neuropathy, CNS, EIB, Schizophrenia, Sale, Plasma protein binding, Electroencephalography, Pharmaceutical industry

Milan, Italy, September 16, 2021, 07:00 am CEST - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its operational highlights and financial results for the half-year ended June 30, 2021.

Key Points: 
  • Milan, Italy, September 16, 2021, 07:00 am CEST - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its operational highlights and financial results for the half-year ended June 30, 2021.
  • In April, Newron announced encouraging results from two short-term explanatory studies in evenamide: study 010 in 56 healthy volunteers, and study 008 in 138 outpatients with chronic schizophrenia, receiving treatment with a second-generation atypical antipsychotic.
  • Based on this encouraging data and supported by the pre-clinical results published last year confirming the absence of toxicity, Newron, on September 6, 2021, initiated study 008A, the first potentially pivotal study with evenamide in patients with chronic schizophrenia.
  • Newron believes that positive results from this study would qualify the trial as the first adequate and well-controlled (pivotal) study with evenamide in patients with schizophrenia who are inadequate responders to antipsychotics.

Medical Electrodes Markets: Electrocardiography, Electroencephalography & Brainstem Auditory Evoked Potential, Electromyography - Global Industry Analysis and Demand Forecast to 2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 26, 2021
Health, Medical Devices, Cardiology, Coronary artery disease, CAGR, Muscle tissue, Population, Electrocardiography, Wireless ambulatory ECG, EEG, ECG, Incidence, Movement, BAEP, EMG, Conditional sentence, Atherosclerosis, Electromyography, Prevalence, Arrhythmia, Heart, Electroencephalography, Degenerative disease, COVID-19, Standstill, Medical device, Medical imaging

The "Medical Electrodes Market Research Report - Global Industry Analysis and Demand Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Electrodes Market Research Report - Global Industry Analysis and Demand Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • Global medical electrodes market is predicted to grow at a 6.7% CAGR between 2021 and 2025, to reach $1,151.6 million by 2025.
  • Rising volume of minimally invasive procedures, booming geriatric population, and increasing prevalence of lifestyle-associated and chronic diseases, the usage of medical electrodes is surging.
  • To be more profitable, players in the medical electrodes market are constantly launching new and improved products.

Nihon Kohden America and CrowdStrike Partner to Implement Best in Class Protection Against Advanced Cyber Threats in Rapidly Changing Healthcare Environments

Retrieved on: 
Wednesday, August 11, 2021
Software, Networks, Internet, Health, Medical Devices, Hospitals, Technology, Security, Industry, Certification, Business development, Electroencephalography, Caregiver, Patient, Efficiency, Partnership, CrowdStrike, Organization, Solution, Artificial intelligence, Compliance, Environment, Quality engineering, Risk management, Medical device

Nihon Kohden recently certified and validated the CrowdStrike Falcon platform and will integrate it into its NK Network CareSM Service.

Key Points: 
  • Nihon Kohden recently certified and validated the CrowdStrike Falcon platform and will integrate it into its NK Network CareSM Service.
  • By integrating with the CrowdStrike Falcon platform, Nihon Kohdens NK NetworkCareSM service is able to protect the most critical assets in its network and minimize disruption to the clinical system.
  • The wide variety of networked medical devices has created a complex environment for healthcare IT departments to navigate, said Scott Silcock, vice president of Service Excellence at Nihon Kohden.
  • We at Nihon Kohden America look forward to having a long-term partnership that improves and evolves with the needs of the market.

Nihon Kohden to Elevate Advancements Towards Improved Patient Outcomes with the Acquisition of Advanced Medical Predictive Devices, Diagnostics and Displays, Inc.

Retrieved on: 
Monday, August 9, 2021
Technology, Medical Devices, Medical Supplies, Hospitals, Software, Practice Management, Other Health, Biotechnology, Health, Data Management, Technology, Vital signs, Software, Population, Continuous monitoring, CEO, Roger Hawkins (drummer), Artificial intelligence, Software as a service, Mortality, Health, Industry, Acquisition, EHR, Algorithm, Patient, Nihon Kohden, HMI, Diagnosis, Machine learning, Research, Ecosystem, Director, Electroencephalography, Risk management, 3D printing, Medical imaging, Nihon Kohden Corporation, Nihon Kohden Digital Health Solutions, Inc., NIHON KOHDEN CORPORATION, NIHON KOHDEN DIGITAL HEALTH SOLUTIONS, INC.

Were creating a digital health focused ecosystem of care, said Harsh Dharwad, President and CEO of Nihon Kohden Digital Health Solutions, Inc.

Key Points: 
  • Were creating a digital health focused ecosystem of care, said Harsh Dharwad, President and CEO of Nihon Kohden Digital Health Solutions, Inc.
  • Nihon Kohden exists to empower clinicians with continuous patient data and intelligent devices that accompany patients every step of the way.
  • As innovation in technology progresses, Nihon Kohden will continue to evolve their advanced products and services for the benefit of all.
  • Established in 1999, Nihon Kohden Digital Health Solutions, Inc. creates innovative and data driven software solutions to complement the full range of Nihon Kohden Corporations leading medical technologies.

Global Electroencephalography (EEG) Devices Markets 2021-2025 - Increasing Popularity of Hybrid Brain-computer Interface Techniques - ResearchAndMarkets.com

Retrieved on: 
Friday, August 6, 2021
Medical Devices, Health, Industry, Prevalence, CAGR, Solution, Medtronic, Electroencephalography, EEG, USD, Lists of diseases, Retail, Medical imaging

The "Global Electroencephalography (EEG) Devices Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Electroencephalography (EEG) Devices Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The report on the electroencephalography (EEG) devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The electroencephalography (EEG) devices market analysis includes the product segment and geographic landscape.
  • This study identifies the increasing popularity of hybrid brain-computer interface techniques as one of the prime reasons driving the electroencephalography (EEG) devices market growth during the next few years.

NeuroPace Launches nSight Platform and Partnership with Seizure Tracker™ to Provide Doctors With Personalized Information About Their Patients’ Seizure Burden

Retrieved on: 
Wednesday, August 4, 2021
Data Management, Health, Technology, Mobile, Wireless, Software, General Health, Epilepsy, Branches of biology, Medicine, Clinical medicine, Seizure, the RNS® System, NeuroPace, Inc., Seizure Tracker™, THE RNS® SYSTEM, NEUROPACE, INC., SEIZURE TRACKER™

As part of the nSight Platform offering, NeuroPace has partnered with Seizure Tracker , one of the most widely used electronic seizure diary apps, to help patients and clinicians more reliably track and manage seizures.

Key Points: 
  • As part of the nSight Platform offering, NeuroPace has partnered with Seizure Tracker , one of the most widely used electronic seizure diary apps, to help patients and clinicians more reliably track and manage seizures.
  • Through the companies partnership, patients can elect to share Seizure Tracker information with their physicians through the nSight Platform.
  • For epilepsy patients, Seizure Tracker can provide a convenient way to track daily seizure activity and share this information with their doctor.
  • Reports generated on the Seizure Tracker system provide extensive data visualizations comparing therapies against seizure activity changes while highlighting trends.

Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome

Retrieved on: 
Monday, August 2, 2021
Health, Life sciences, Lennox–Gastaut syndrome, LGS, EPX, Epilepsy, Orphan drug, Lennox

PARAMUS, N.J., Aug. 2, 2021 /PRNewswire/ --Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to EPX-200 for the treatment of Lennox-Gastaut Syndrome (LGS).

Key Points: 
  • PARAMUS, N.J., Aug. 2, 2021 /PRNewswire/ --Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to EPX-200 for the treatment of Lennox-Gastaut Syndrome (LGS).
  • "Granting Orphan Drug Designation for LGS to EPX-200 is one of the company's significant development milestones, because the Company is expanding targeted indications to multiple refractory epilepsies, including LGS.
  • The FDA's ODD grant to EPX-200 for LGS recognizes the significance of EPX-200 as a drug candidate for these patients.
  • EPX-200 also has been reported to have anti-seizure effects based on the result from small number of patients.

Assure Holdings Performs First Neuromonitoring Case in Nebraska

Retrieved on: 
Thursday, July 29, 2021
Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, Branches of biology

DENVER, July 29, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that it has performed its first neuromonitoring case in the state of Nebraska.

Key Points: 
  • DENVER, July 29, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that it has performed its first neuromonitoring case in the state of Nebraska.
  • Assure is continuing to generate strong organic growth, both by expanding into new states and extending our reach within our current operational footprint.
  • Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries.
  • Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned The Joint Commissions Gold Seal of Approval.

Elite Education Group International Ltd. Announces First Half Fiscal Year 2021 Financial Results and Operational Update

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Brain–computer interfacing, Electroencephalography, Electrophysiology, Neurotechnology, Psychiatric assessment

MIDDLETOWN, Ohio, July 13, 2021 /PRNewswire/ -- Elite Education Group International Limited (Nasdaq:EEIQ) ("EEG"), a provider of comprehensive, one-stop education solutions for Chinese university students interested in study abroad programs in the US and other countries, today announced its first half financial results for the six months ended March 31, 2021 and an operational update.

Key Points: 
  • MIDDLETOWN, Ohio, July 13, 2021 /PRNewswire/ -- Elite Education Group International Limited (Nasdaq:EEIQ) ("EEG"), a provider of comprehensive, one-stop education solutions for Chinese university students interested in study abroad programs in the US and other countries, today announced its first half financial results for the six months ended March 31, 2021 and an operational update.
  • "Our revenue decreased for the first half of fiscal 2021 primarily due to the global Covid-19 pandemic that negatively impacted businesses around the world in 2020.
  • First Half 2021 Financial Results Ended March 31, 2021
    Revenueswere $3.1 million for the first half of fiscal 2021 compared to $6.1 million for the same period of 2020, representing a decrease of $3.0 million, or 49.4%.
  • The decrease was primarily due to the drop inrevenue in the first half of 2021 compared to the same period of 2020.